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Abstract In the development of central nervous system
(CNS)-targeted drugs, the prediction of human CNS target
exposure is a big challenge. Cerebrospinal fluid (CSF) con-
centrations have often been suggested as a ‘good enough’
surrogate for brain extracellular fluid (brainECF, brain target
site) concentrations in humans. However, brain anatomy and
physiology indicates prudence. We have applied a multiple
microdialysis probe approach in rats, for continuous measure-
ment and direct comparison of quinidine kinetics in brainECF,
CSF, and plasma. The data obtained indicated important dif-
ferences between brainECF and CSF kinetics, with brainECF
kinetics being most sensitive to P-gp inhibition. To describe the
data we developed a systems-based pharmacokinetic model.
Our findings indicated that: (1) brainECF- and CSF-to-unbound
plasma AUC0–360 ratios were all over 100 %; (2) P-gp also
restricts brain intracellular exposure; (3) a direct transport route
of quinidine from plasma to brain cells exists; (4) P-gp-medi-
ated efflux of quinidine at the blood–brain barrier seems to
result of combined efflux enhancement and influx hindrance;
(5) P-gp at the blood–CSF barrier either functions as an efflux
transporter or is not functioning at all. It is concluded that in
parallel obtained data on unbound brainECF, CSF and plasma
concentrations, under dynamic conditions, is a complex but
most valid approach to reveal the mechanisms underlying the
relationship between brainECF and CSF concentrations. This
relationship is significantly influenced by activity of P-gp.
Therefore, information on functionality of P-gp is required for
the prediction of human brain target site concentrations of P-gp
substrates on the basis of human CSF concentrations.
Keywords Pharmacokinetics  Blood–brain barrier 
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List of symbols
Variables
Ai Amount of quinidine in compartment i (ng)
Ci Concentration of quinidine in compartment i (ng/ml)
K Rate constant (min-1)





PL,u Unbound quinidine in plasma








To be able to predict desired or undesired central nervous
system (CNS) drug effects in humans, a mechanistic
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understanding is needed of the individual contributions of
the processes involved in brain target site distribution and
ultimately drug effects. With the unbound drug concen-
trations at the brain target site being responsible for the
(un)wanted effect it is important to be able to determine or
predict unbound drug concentrations at their site of action.
During the preclinical phase of drug development sev-
eral techniques can be applied to determine or predict brain
target site concentrations, which are often closely linked, or
equal, to brain extracellular fluid (brainECF) concentrations
[1, 2]. However, most of the preclinical techniques have
very limited applicability in the extrapolation of preclinical
findings to the human situation [3–5].
Cerebrospinal fluid (CSF) concentrations are often
considered to be the best available surrogate for brain
target site concentrations in humans [6–10]. It is often
assumed that CSF concentrations readily equilibrate with
brain ECF concentrations due to the lack of a physical
barrier between these sites [11]. However, due to qualita-
tive and quantitative differences in processes that govern
the pharmacokinetics (PK) of drugs in the brain, a gener-
ally applicable relationship between CSF concentrations
and brain ECF concentrations does not exist [5, 12–14].
Transport of drugs into and out of the brain is not solely
governed by the blood–brain barriers [the blood–brain
barrier (BBB) and the blood–CSF barrier (BCSFB)], but
also by the anatomy of the brain and physiological pro-
cesses. In combination with drug specific properties [15–19],
this determines the concentrations of a drug within a specific
part of the CNS, including the target site concentrations,
which we are ultimately interested in.
We have previously shown that even for acetaminophen,
a model compound for passive transport into, within and
out of the brain, differences exist between CSF and brai-
nECF kinetics [20]. For compounds subjected to active
transport at the level of the brain barriers, such as by P-gp,
differences between brainECF and CSF are anticipated to be
larger. With P-gp localized at both the luminal and ablu-
minal membranes of capillary endothelial cells, as well as
to adjacent pericytes and astrocytes [21], this suggests that
P-gp may regulate drug transport processes in the entire
brain at both the cellular and subcellular level. In contrast,
P-gp presence and localization at the BCSFB is still subject
of debate, with the only report of presence at the apical
surface of the choroid plexus epithelial cells in the rat by
Rao and colleagues [22]. Furthermore, it has been well
established that P-gp functions as an efflux transporter at
the BBB [23–26], whereas, there has been some evidence
that P-gp could function as an influx transporter at the
BCSFB [22, 27]. This could result in significant differences
between concentrations at the brain target site and in CSF
for compounds that are substrates for P-gp mediated
transport.
The presence of P-gp at multiple sites, with in part a yet
uncertain transport direction, could have major implica-
tions for the predictability of human brainECF concentra-
tions on the basis of human CSF concentrations for
compounds that are substrates for P-gp. Consequently, to
be able to predict human brainECF concentrations on the
basis of human CSF concentrations, one should first
understand the mechanisms that determine the relationship
between CSF concentrations and brainECF concentrations.
Previous studies have indicated that, under steady-state
conditions, CSF concentrations were comparable to steady-
state brainECF concentrations for compounds that freely
diffuse across the BBB and BCSFB, but may differ for
compounds that are substrate for the various active trans-
port systems at the BBB and BCSFB [6–10]. CSF and
brainECF concentration ratios were considered comparable
if smaller than threefold, and assumed to be of little
pharmacological consequence.
However, we have previously questioned this arbitrary
threefold range in ratio of CSF and brainECF (target site)
kinetics, especially with regard to the unknown impact of
the steady-state situation versus the more realistic multiple
dosing conditions (troughs and peaks), the unknown of the
changes therein in disease conditions as well as the
unknown impact of this range on pharmacodynamics [5].
These unknowns need to be investigated before we can
really predict human target site PK and finally CNS effects.
Using the multiple intracerebral probe microdialysis
approach [striatum (ST), lateral ventricle (LV), and cis-
terna magna (CM)] with parallel blood sampling, contin-
uous measurement and direct comparison of changes in
concentrations in plasma, brainECF and CSF kinetics of
quinidine, a well-known P-gp substrate [28–32], could be
assessed, following a short infusion of 10 and 20 mg/kg,
with and without co-administration of the P-gp blocker
tariquidar [33, 34]. Mathematical modelling was applied to
the data to result in a number of key findings.
Materials and methods
Chemicals
Tariquidar (XR9576, TQD) was obtained from Xenova
Group PLC (Cambridge, England) or API Services Inc.
(Westford, USA). Quinidine, quinidine sulfate dehydrate,
quinidine hemi sulfate and quinine hemi sulfate were
obtained from Sigma Aldrich (Zwijndrecht, The Nether-
lands). Triethyl amine was obtained from J.T. Baker
(Deventer, The Netherlands). Boric acid and orthophos-
phoric acid 85 % were obtained from Merck (Darmstadt,
Germany). Methyl tert-butyl ether was obtained from
Biosolve B.V. (Valkenswaard, The Netherlands). Isoflurane
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was obtained from Pharmachemie B.V. (Haarlem, The
Netherlands). Saline and 5 % glucose were obtained from
the Leiden University Medical Centre pharmacy (Leiden,
The Netherlands). Microdialysis perfusion fluid was pre-
pared as previously described [20], containing 140.3 mM
sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM
magnesium and 147.7 mM chloride.
Animals
The study protocol was approved by the Animal Ethics
Committee of Leiden University (UDEC nr. 07142) and all
animal procedures were performed in accordance with
Dutch laws on animal experimentation. A total of 60 male
Wistar WU rats (225–275 g, Charles River, Maastricht,
The Netherlands) were randomly divided into two groups;
the first group (n = 12) was used for the determination of
the in vivo microdialysis probe recovery; the second group
(n = 48) was used for brain disposition experiments. This
second group was further divided into four subgroups,
designated for 10 or 20 mg/kg quinidine with or without
co-administration of tariquidar (10-, 10?, 20- and 20?).
After arrival, all animals were housed in groups for
5–7 days (Animal Facilities, Gorlaeus Laboratories, Lei-
den, The Netherlands), under standard environmental
conditions (ambient temperature 21 C; humidity 60 %;
12/12 h light/dark cycle, background noise, daily han-
dling), with ad libitum access to food (Laboratory chow,
Hope Farms, Woerden, The Netherlands) and acidified
water. Between surgery and experiments, the animals were
kept individually in Makrolon type three cages for 7 days
to recover from the surgical procedures.
Surgery
All surgical procedures were performed as described by
Westerhout et al. [20]. In short, cannulas were implanted in
the left femoral artery and vein for blood sampling and
drug administration, respectively. Both cannulas were
subcutaneously led to the back of the head and fixated in
the neck with a rubber ring. Subsequently, the animals
were chronically instrumented with two CMA/12 micro-
dialysis guides (CMA/Microdialysis AB, Stockholm,
Sweden) in different combinations of ST, for sampling in
brain ECF, and LV and/or CM for sampling in CSF
(ST ? LV, ST ? CM or LV ? CM). For ST, the position
of the microdialysis guide is: 1.0 mm anterior, 3.0 mm
lateral, 3.4 mm ventral, relative to bregma. For LV, the
position of the microdialysis guide is: 0.9 mm posterior,
1.6 mm lateral, 2.9 mm ventral, relative to the bregma. For
CM, the position of the microdialysis guide is: 1.93 mm
posterior, 3.15 mm lateral, 8.1 mm ventral, at an angle of
25 from the dorsoventral axis (towards anterior) and 18
lateral from the anteroposterior axis relative to lambda. The
microdialysis guides were secured to the skull with 3
anchor screws and dental cement.
After the surgery the animals received 0.03 ml Temgesic
intramuscularly (Schering-Plough, Amstelveen, The Neth-
erlands) and 0.3 ml Ampicillan (Alfasan B.V., Woerden,
The Netherlands) subcutaneously. One day prior to the
experiment, the microdialysis dummies were replaced by the
microdialysis probes (CMA/12 Elite, Polyarylethersulfone,
molecular weight cut-off 20 kDa, CMA/Microdialysis AB,
Stockholm, Sweden, with a semi-permeable membrane
length of 4 mm for ST, and 1 mm for LV and CM).
Experimental set-up
All experiments were performed as described by West-
erhout et al. [20], with some modifications. In short, the
in vivo microdialysis probe recovery of quinidine was
determined on the basis of reverse dialysis [35]. The
microdialysis probes in ST, LV and CM were perfused
with different concentrations of quinidine (50, 200 and
1000 ng/ml) in perfusion fluid. To evaluate the potential
effect of co-administration of tariquidar on the in vivo
recovery of quinidine, several animals received an intra-
venous infusion of 15 mg/kg in 5 % glucose solution
(100 ll/min/kg for a period of 10 min) with an automated
pump (Pump 22 Multiple Syringe Pump, Harvard Appa-
ratus, Holliston, USA) 30 min prior to the start of the
reverse dialysis experiment. Control animals received an
intravenous infusion of vehicle (100 ll/min/kg for a period
of 10 min).
The in vivo recovery is defined as the ratio of the con-
centration difference between the dialysate (Cdial) and per-
fusion fluid (Cin) over the concentration in the perfusion fluid
(Eq. 1) [36].
In vivo recovery ¼ Cin  Cdial
Cin
ð1Þ
For the brain disposition experiments, the rats first received
an intravenous infusion of 15 mg/kg tariquidar in 5 % glu-
cose solution or vehicle 30 min prior to the administration of
10 or 20 mg/kg quinidine in saline (100 ll/min/kg for a
period of 10 min). The start and duration of the infusion was
corrected for internal volume of the tubing so that infusion
started at t = 0 min. 10 min interval samples were collected
between t = -1 h to t = 4 h, followed by 20 min interval
samples from t = 4–6 h. After weighing the microdialysis
vials they were stored at -80 C before analysis.
For the determination of quinidine plasma concentrations,
blood samples of 100 ll were taken, in parallel to the micro-
dialysate samples, from the arterial cannula at t = -5 (blank),
2, 7, 10, 12, 17, 30, 60, 140, 240, and 360 min. All blood
samples were temporarily stored in heparin (10 IU) coated
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Eppendorf cups before being centrifuged for 15 min at
5,000 rpm. The plasma was then pipetted into clean Eppendorf
cups and stored at -20 C before analysis.
At the end of the experiments the animals were sacri-
ficed with an overdose of Nembutal (Ceva Sante Animale,
Libourne, France). The animals were then perfused and
decapitated to isolate the brain. After cleaning with saline,
weighing, and freezing in liquid nitrogen, the brain was
stored at -80 C before analysis.
Plasma protein binding
For the determination of plasma protein binding of quini-
dine, blood samples of 300 ll were taken at t = -30
(blank) and 60 min (with a concentration assumed to be
approximately 1/2 9 Cmax [37]). After the blood sample at
t = 360 min, an additional dose of 10 or 20 mg/kg in
10 min was given to be able to determine plasma protein
binding at Cmax (at t = 370 min). All blood samples were
temporarily stored in heparin (10 IU) coated Eppendorf
cups. The blank blood samples were spiked with quinidine
to obtain a blood concentration of 100 ng/ml for the
10 mg/kg dose group and 200 ng/ml for the 20 mg/kg dose
group. The spiked blood samples were then incubated in a
shaking water bath at 37 C for 30 min. All blood samples
were centrifuged for 15 min at 5,000 rpm and the plasma
was pipetted into clean Eppendorf cups and stored at
-20 C before analysis.
Plasma protein binding was determined with Centri-
free ultrafiltration devices (Millipore BV, Etten-Leur, the
Netherlands). All procedures were performed according to
the user’s manual. The ultrafiltrate was diluted ten times
with saline before the analysis.
Concentration analysis
Quinidine concentrations in plasma, plasma ultrafiltrate,
microdialysate, and total brain were determined as descri-
bed by Syva¨nen et al. [32], using high pressure liquid
chromatography (HPLC) with fluorescence detection. In
short, to 20 ll of plasma, 50 ll internal standard (IS;
500 ng/ml quinine) was added. After homogenization with
200 ll borate buffer pH 10, 5 ml of methyl tert-butyl ether
was added. After vortexing, centrifugation, and freezing of
the aqueous layer, the organic phase was evaporated to
dryness. The extracts were reconstituted in 100 ll of
mobile phase and centrifuged at 4,0009g during 5 min.
The clean plasma extracts were injected using a mobile
phase with an acetonitrile/buffer ratio of 1:6.
To 20 ll of the plasma ultrafiltrate or microdialysate
samples 20 ll IS was added, followed by vortexing before
being directly injected into the HPLC system. Quinidine
concentration in brain tissue was analyzed by the following
steps: whole brain was homogenized in 50 mM phosphate
buffer at pH 7.4. To 600 ll of the homogenate 100 ll IS
and 100 ll 1 M sodium hydroxide was added. 5 ml methyl
tert-butyl ether was then added, followed by vortexing and
centrifugation. 4 ml of the supernatant was then transferred
to a clean glass tube and 100 ll of 30 mM phosphoric acid
was added. After vortexing and centrifugation, the super-
natants were aspirated and discarded. The remaining
aqueous phase was centrifuged for 10 min at 11,0009g. An
aliquot of 50 ll was then transferred to clean glass vials
and 20 ll was injected into the HPLC system.
Data acquisition and processing was performed using
Empower data acquisition software (Waters, Etten-Leur,
The Netherlands). For constructing the calibration curve,
linear regression analysis was applied using weight factor
1/(y)2. Data analysis, statistical analysis, and plotting were
performed using Microsoft Office Excel 2003 (Microsoft
Corporation, USA).
PK data analysis
All plasma concentrations were converted to unbound
plasma concentrations, by correction for plasma protein
binding. All microdialysate concentrations from ST, LV
and CM were converted into brain ECF concentrations
(CECF) or CSF concentrations (CCSF) by division of the
dialysate concentrations by the average in vivo recovery as
determined for each microdialysis probe location (Eq. 2).
CECF or CCSF ¼ Cdial
in vivo recovery
ð2Þ
Areas under the curve from t = 0 to t = 360 min
(AUC0–360) were calculated by the trapezoidal rule and
tested for differences by single factor ANOVA. The pop-
ulation PK models were developed and fitted to the data by
means of non-linear mixed-effects modeling using the
NONMEM software package (version 6.2, Icon Develop-
ment Solutions, Ellicott City, Maryland, USA) and ana-
lyzed using the statistical software package S-Plus for
Windows (version 6.2 Professional, Insightful Corp.,
Seattle, USA).
The PK model for quinidine plasma and brain concen-
trations was based on the systems-based PK (SBPK)
approach we have previously applied to investigate the
exchange between brain ECF and CSF of acetaminophen
[20]. For this approach, the volumes of the different brain
compartments were fixed to their physiological volumes.
The rat brain intracellular space and brainECF volume were
assumed to be 1.44 ml [38] and 290 ll [39], respectively.
With a total CSF volume of 300 ll in the rat [40], the
volumes of the LV, third and fourth ventricles, CM and
subarachnoid space were assumed to be 50 ll [41, 42],
50 ll [43], 17 ll [44, 45] and 180 ll [40, 43], respectively.
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The intra-brain distribution was restricted by the physio-
logical flow paths of brain ECF, in which brain ECF flows
towards the CSF compartments at a rate of 0.2
ll/min [39, 46], and CSF flows from LV, through the third
and fourth ventricle, to the CM and subsequently to the
subarachnoid space (cranial and spinal) and back into
blood at a rate of 2.2 ll/min [47].
Structural model selections for both the blood and brain
PK model were based on the likelihood ratio test (p \ 0.01),
diagnostic plots (observed concentrations vs. individual and
population predicted concentrations, weighted residuals vs.
predicted time and concentrations), parameter correlations
and precision in parameter estimates. The inter-animal
variability in PK parameters was assumed to be log nor-
mally distributed. The residual error, which accounts for
unexplained variability (e.g. measurement and experimental
error and model-misspecification), was best described with
a proportional error model.
The validity of the PK models was investigated by
means of a visual predictive check [48–50]. Using the final
PK parameter estimates, 1,000 curves were simulated.
Subsequently, the median and the 5th and 95th percentile
of the predicted concentrations were calculated, which
represent the 90 % prediction interval. These were then
compared with the observations.
In order to test the ruggedness of the model and estimate
the precision of the parameters n = 100 non-parametric
(case resampling) bootstraps were performed. To create the
bootstrapped datasets, specific rat data (plasma and
microdialysate concentrations) were removed randomly
from the datasets and replaced with randomly selected rat
data from the complete original dataset. Each of these
permutations of the original dataset were fitted with the
final model determined based on the original dataset. This
results in a series of model fits, each with its own set of
parameters. These results were displayed graphically and
the descriptive statistics of the parameters were compared
to parameter estimates of the final model. Only bootstrap
runs that successfully minimized were used in this analysis.
Results
All results are presented as average values ± standard
error of the mean, unless stated otherwise.
Quinidine PK
The average unbound plasma (plasmau) and unbound brain
(brainu) quinidine concentrations following the 10 and 20
mg/kg dose with or without co-administration of tariquidar are
shown in Fig. 1. Plasma protein binding of quinidine was
linear at an extent of 86.5 ± 5.5 %. It was not affected by
co-administration of tariquidar. The co-administration of
tariquidar slightly reduced the plasma elimination rate of
plasmau for both 10 and 20 mg/kg dose of quinidine. Data
obtained by microdialysis from the brainECF, LV (CSFLV) and
CM (CSFCM) were corrected for in vivo recovery. The aver-
age in vivo recoveries for the brainu concentrations in ST, LV
and CM probes were not influenced by co-administration of
tariquidar and were determined to be 9.1 ± 0.5, 2.9 ± 0.5 and
3.5 ± 0.5 %, respectively.
It can be seen that a higher dose of quinidine leads to
higher brainu quinidine concentrations in all brain com-
partments, but not to the same extent. Tariquidar increased
all brainu quinidine concentrations significantly (p \ 0.01),
but most pronouncedly for brainECF. The effect of tariquidar
Fig. 1 Average (geometric mean ± SEM) unbound quinidine con-
centration–time profiles following intravenous administration of
quinidine, with (?) or without (-) co-administration of tariquidar
(15/mg/kg). a 10 mg/kg quinidine dose: for plasma (n = 11 (-) and 6
(?)), brainECF (n = 6 (-) and 4 (?)), CSFLV (n = 4 (-) and 3 (?))
and CSFCM (n = 4 (-) and 4 (?). b 20 mg/kg quinidine dose. Plasma
(n = 9 (-) and 11 (?)), brainECF (n = 5 (-) and 6 (?)), CSFLV
(n = 4 (-) and 4 (?)) and CSFCM (n = 6 (-) and 6 (?))
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was dependent on the quinidine dose; at the higher dose of
quinidine, the increase in brainu quinidine concentrations
was less profound, as can be seen by the average brainu-to-
plasmau AUC0–360 ratios (Table 1). However, the differ-
ence between the brainu-to-plasmau AUC0–360 ratios for the
10 and 20 mg/kg dose with co-administration of tariquidar
was only significant (p \ 0.05) for brainECF. The relation-
ship between brainECF-to-CSF concentrations ratios was
also very much dependent on tariquidar, and on average
were increased from 0.77 ±0.19 to 2.41 ± 0.56 and from
0.67 ± 0.21 to 2.02 ± 0.52, for the 10 and 20 mg/kg dose,
respectively (Table 2). Significant differences in AUC
ratios and concentrations between brainECF and CSF (either
from LV or CM) were only observed for the groups that
received the co-administration of tariquidar.
Also, end-of-experiment total brain concentrations (braintotal)
were obtained. These data were corrected for corresponding
brainECF concentrations to represent deep brain (braindeep)
concentrations. The braindeep concentrations were deter-
mined to be on average 3.6 ± 1.6-fold higher than final
brainECF concentrations for the control group and 6.3 ± 1.5-
fold higher for the animals that received a co-administration
of tariquidar (not significantly different). This indicates that
P-gp also influences brain intracellular exposure.
Compartmental modeling approach
All data were subjected first to compartmental PK analysis.
It was shown that the plasma concentrations were best
described by a three compartment model with inter-com-
partmental clearance (Q), and elimination clearance from
the central compartment (CLE). The effect of the
co-administration of tariquidar on the elimination clearance
was found to be significant (p \ 0.01, OF value reduction
of 6.63 units).
To describe the concentrations in each of the brain
compartments, four brain compartments were added
(brainECF, CSFLV, CSFCM and braindeep). Drug transport
between the plasma and the different brain compartments
was determined by a transfer clearance between plasma
and each of the brain compartments (CLPL–BR) and vice
versa (CLBR–PL). In this model (Fig. 2) it was not possible
to include drug transport between the different brain
compartments because each brain compartment then has
multiple routes of entry. The model was not able to identify
the specific contribution of each route, resulting in transfer
clearance value estimations near 0, which is not realistic.
Therefore, we decided to remove the transport between the
different brain compartments.
Distinction between passive and active transport
clearances
The effect of P-gp on the different transfer clearances
between plasma and the brain compartments was deter-
mined by comparing the parameter estimations for the rats
that did to those rats that did not receive the co-adminis-
tration of tariquidar. Thus, a distinction could be made
between the passive and the active component of the
transfer clearances.
The data were best described by a model in which P-gp
reduced the transfer clearance from plasma to the brain
compartments (i.e. influx hindrance) and increased the
transfer clearance from the brain compartments to plasma
(i.e. efflux enhancement). The transfer clearances between
Table 1 Brainu-to-plasmau AUC0–360 ratios for brain ECF, CSFLV and CSFCM for the 10 and 20 mg/kg dose without (-) and with (?)
co-administration of tariquidar
Brainu-to-plasmau AUC0–360 ratios 10
- (%) 10? (%) 20- (%) 20? (%)
BrainECF 135 ± 17 1,265 ± 213**
, 150 ± 16 864 ± 64**,
CSFLV 177 ± 39 624 ± 41** 257 ± 24 498 ± 74**
CSFCM 167 ± 16 479 ± 76** 184 ± 15 383 ± 33**
** Significantly (p \ 0.01) different from the group without co-administration of tariquidar
 Significantly (p \ 0.05) different from the CSF-to-plasmau AUC0–360 ratios
 Significantly (p \ 0.05) different from the 10 mg/kg dose group with co-administration of tariquidar
Table 2 BrainECF-to-CSF concentration ratios for the 10 and 20 mg/kg dose without (-) and with (?) co-administration of tariquidar
BrainECF-to-CSF concentration ratios 10
- 10? 20- 20?
BrainECF-to-CSFLV 0.75 ± 0.09* 2.13 ± 0.47* 0.56 ± 0.18* 1.81 ± 0.57
BrainECF-to-CSFCM 0.79 ± 0.25 2.70 ± 0.51* 0.78 ± 0.17 2.23 ± 0.37*
BrainECF-to-CSFaverage 0.77 ± 0.19 2.41 ± 0.56* 0.67 ± 0.21 2.02 ± 0.52*
* Significantly (p \ 0.05) different from 1
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plasma and the different brain compartments that could be
assigned to P-gp were incorporated into the model as
previously described by Syva¨nen et al. [51]:
CLPLBR ¼ CLPLBR;p  CLPLBR;Pgp ð3Þ
CLBRPL ¼ CLBRPL;p  CLBRPL;Pgp ð4Þ
where the subscript ‘p’ denotes passive transport and
‘P-gp’ denotes P-gp-mediated transport.
Modeling quinidine concentration-dependent
P-gp-mediated transport
Since P-gp-mediated transport is an active (saturable)
process we have also tried to identify the maximal transport
rate (Tm) and the blood- or brain concentration for half-
maximal transport (Km) as follows:
CLPLBR;Pgp ¼ Tm;PLBR
Km;PLBR þ CPL;u ð5Þ
CLBRPL;Pgp ¼ Tm;BRPL
Km;BRPL þ CBR ð6Þ
where CPL,u is the unbound plasma concentration and CBR
is the concentration in one of the brain compartments. The
parameter estimations of Tm and Km resulted in high values
for both Tm and Km (results not shown), indicating that the
plasma and brain concentrations in this study are not suf-
ficiently high for saturating P-gp-mediated transport. The
parameter estimations of Tm and Km also resulted in too
large coefficients of variation. Thus, our data were insuf-
ficient to determine the values of these parameters, and for
the next modeling steps, P-gp-mediated transport had to be
incorporated by means of a single clearance value, rather
than by Tm and Km.
Modeling deep brain concentrations
Braindeep concentrations were determined for samples obtained
at the end-of-experiment time point. Based on previous studies
in our lab with male Wistar WU rats (unpublished results), it
was found that the braindeep-to-brainECF concentration ratio of
quinidine was constant throughout the entire experimental
period. We used this information to estimate braindeep con-
centrations during the experiment.
Final compartmental model
The final estimation of the PK parameters of the com-
partmental model is summarized in Table 3. The visual
predictive check of the final compartmental model is given
in Fig. 3. It can be seen that the compartmental model
describes the data very well within the 95 % prediction
interval, and also can cope with the large inter-individual
variation as observed in the different brain concentrations.
The goodness of fit plots of the plasma, brainECF, CSFLV,
CSFCM and brainECF data with the compartmental model
are available as supplemental material.
Systems-based modeling approach
As it was our goal to investigate the relationship between
brainECF and CSF PK, we have applied a SBPK modeling
approach. To more adequately describe CSF physiology, we
have added two CSF compartments that represent the
combined third and fourth ventricle (CSFTFV) and the
subarachnoid space (CSFSAS), like we did previously for
analysis of acetaminophen regional brain distribution [20].
Since we have no measurements of the concentrations in the
third and fourth ventricle, the transfer clearance between
plasma and third and fourth ventricle was assumed to be
equal to the transfer clearance between plasma and LV.
Modeling CSF flow
In our first attempt of the SBPK approach the values of the
brain ECF flow (QECF) and CSF flow (QCSF) were fixed to
their physiological values. However, it appeared that this
value for QCSF was too high for proper description of
quinidine concentration in the CSF compartments.
Fig. 2 Diagram of the compartmental model that was used to
describe the brain distribution of quinidine in the rat. CLE is the
elimination clearance from plasma, QPL–PERx is the inter-compart-
mental clearance between plasma and the first (x = 1) or second
(x = 2) peripheral compartment. Further, for transfer clearances
between compartments (CLfrom comp-to comp), denotations of the
compartments are: PL plasma; ECF brainECF; DBR braindeep; LV
lateral ventricle; and CM cisterna magna. For peripheral and plasma
compartments, V volume of distribution; for brain compartments,
V physiological volume, not being shown in the model
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Therefore the CSF production rate was estimated. To do so,
the clearance from CSFLV to plasma was fixed to 0, as
otherwise QCSF was estimated to be 0. Thereby, the model
was ‘forced’ to estimate the QCSF, being 0.52 ± 0.25
ll/min. This value of QCSF was much lower than the
physiological one (2.2 ll/min). An explanation for the
reduced QCSF was searched for. It was found that quinidine
is capable of inhibiting Na?-K?-ATPase activity [53],
which is an enzyme at the apical membrane of the choroid
plexus that leads to the formation of CSF [54, 55]. A
potential influence of quinidine reducing CSF flow was
investigated by a CSF quinidine concentration (CCSF)-
dependent inhibition of QCSF by means of an Emax model
(Eq. 7), in which QCSF,EF was the effective CSF flow.




The resulting estimated IC50 of quinidine was 209 ± 66 ng/ml.
This value was 143-fold lower than reported (*30 lg/ml, [53])
and not considered realistic. As an alternative, we needed to fix
the QCSF to its physiological value and to define the rate of
transfer of quinidine from blood to CSFLV and vice versa being
equal.
Modeling P-gp-mediated transport
P-gp has been well described as an efflux transporter at the
BBB [23–26]. However, the mechanism by which P-gp can
exert its effect could be by so-called efflux enhancement or
influx hindrance or both. The data were best described by
the model with P-gp function solely as influx hindrance or
combined influx hindrance and efflux enhancement. The
observation that in vivo probe recovery of quinidine was
not affected by tariquidar would be an indication that
quinidine is transported by P-gp only via the influx hin-
drance mechanism [28, 56, 57]. However, as the largest
reduction in the objective function value in the model was
observed for a combined influx hindrance and efflux
enhancement, this indicates that this model is most prob-
ably the best.
Based on the suggestion that P-gp functions as an influx
transporter at the BCSFB [22, 27], the effect of P-gp on the
clearance values between plasma and CSF was described
as such. However, with our data we could not identify P-gp
influx at the BCSFB. Therefore, we have tested models in
which P-gp was considered to be an efflux transporter at
the BCSFB or not present at the BCSFB at all. The data
were best described by a model with P-gp as an efflux
transporter at the BCSFB for LV, whereas it was absent for
CM.
Again, we have tried to identify Tm and Km values for
P-gp-mediated transport of the SBPK model, but without
success (results not shown). Therefore, P-gp-mediated
transport had to be incorporated by means of a single
clearance value, rather than by Tm and Km.
Table 3 Final estimation of the rat PK parameters for the compart-
mental model (±standard error)
Parameter Value
CLE 158 ± 11 ml/min
P-gp effect on CLE 1.2 ± 0.1-fold increase
QPL–PER1 822 ± 95 ml/min
QPL–PER2 171 ± 28 ml/min
CLPL–DBR,p 1,430 ± 188 ll/min
CLPL–DBR,P-gp 1,270 ± 165 ll/min
CLDBR–PL,p 16.1 ± 1.3 ll/min
CLDBR–PL,P-gp 17.3 ± 2.4 ll/min
CLPL–ECF,p 36.6 ± 3.9 ll/min
CLPL–ECF,P-gp 25.8 ± 3.7 ll/min
CLECF–PL,p 3.2 ± 0.2 ll/min
CLECF–PL,P-gp 4.4 ± 0.7 ll/min
CLPL–LV,p 3.4 ± 0.7 ll/min
CLPL–LV,P-gp 1.1 ± 0.3 ll/min
CLLV–PL,p 0.4 ± 0.09 ll/min
CLLV–PL,P-gp 0.5 ± 0.2 ll/min
CLPL–CM,p 0.7 ± 0.08 ll/min
CLPL–CM,P-gp 0.07 ± 0.02 ll/min
CLCM–PL,p 0.1 ± 0.02 ll/min
CLCM–PL,P-gp 0.2 ± 0.06 ll/min
VPL 10.6 ml [52]
VPER1 5.9 ± 0.5 l
VPER2 11.7 ± 1.6 l
VDBR 1.44 ml [38]
VECF 290 ll [39]
VLV 50 ll [41, 42]
VCM 17 ll [44, 45]
gCLE 0.08 ± 0.02
ePL 0.13 ± 0.02
eDBR 0.06 ± 0.01
eECF 0.05 ± 0.01
eLV 0.09 ± 0.02
eCM 0.07 ± 0.01
Parameter values in italic are derived from literature. CLE is the
elimination clearance from plasma, QPL–PERx is the inter-compart-
mental clearance between plasma and the first (x = 1) or second
(x = 2) peripheral compartment. Further, for transfer clearances
between compartments (CLfrom comp-to comp), denotations of the
compartments are: PL plasma; ECF brainECF; DBR braindeep; LV
lateral ventricle; and CM cistern magna. For peripheral and plasma
compartments, V volume of distribution; for brain compartments,
V volume. gi inter-individual variability of parameter i; ej residual
error on concentrations in compartment j. The additional subscripts
‘p’ and ‘P-gp’ denote passive transport and P-gp-mediated transport,
respectively
334 J Pharmacokinet Pharmacodyn (2013) 40:327–342
123
Modeling deep brain concentrations
Our assumption was that compounds, after passing the BBB
and BCSFB would first enter brainECF, before reaching the
braindeep compartment. However, since the braindeep con-
centrations are much higher than the brainECF concentrations,
and the physiological volume of the braindeep compartment is
much larger than the brainECF compartment, the mass
transfer of quinidine from plasma, via the brainECF com-
partment, to the deep brain needs to be quite substantial. This
route did not result in a model that could adequately describe
the data. In contrast, a direct mass transfer from plasma into
the braindeep compartment did. Actually, the direct route
through lipid membranes seems a rather plausible explana-
tion for a lipophilic drug like quinidine, which has a logP of
2.36 in its neutral form [58].
Final SBPK model
The final SBPK model is shown in Fig. 4. The differential
equations of this model can be found in the appendix. The
final estimation of the PK parameters is summarized in
Table 4. Here, the parameters are the same as for Table 3,
with the addition of the following: CLPL–TFV is the clear-
ance from plasma to CSFTFV, CLTFV–PL is the clearance
from CSFTFV to plasma, QECF is the flow rate of brain ECF,
QCSF is the flow rate of CSF, VTFV is the volume of the
third and fourth ventricle combined and VSAS is the volume
of the subarachnoid space.
The visual predictive check of the final model is given in
Fig. 5. It can be seen that the final model describes the data
very well within the 95 % prediction interval, and also can
cope with the large inter-individual variation in brain
concentrations. The goodness of fit plots of the plasma,
brainECF, CSFLV, CSFCM and brainECF data with the final
SBPK model are available as supplemental material.
Discussion
In the development of CNS-targeted drugs, the prediction
of human CNS target exposure is a big challenge. While
CSF concentrations are often considered to be the best
available surrogate for brain target site concentrations in
humans, a generally applicable relationship between CSF
concentrations and brainECF concentrations does not exist.
[5, 12–14] Previous studies have indicated that, at steady-
state conditions, CSF to brainECF concentration ratios were
between threefold (either higher or lower) for compounds
that freely diffuse across the BBB and BCSFB, while for
compounds being brain barrier transporter substrates the
difference may be higher [6–10]. Combining their data
showed that 24 % (21/89) of the P-gp substrates had a
CSF-to-brainECF concentration ratio larger than 3. Then,
prediction of brainECF concentrations on the basis of CSF
concentrations gets inadequate. This indicates that we need
to improve our understanding of the impact of P-gp func-
tionality at the brain barriers in order to be able to predict
human CNS brainECF concentrations.
By using the multiple microdialysis probe approach
[20], we investigated the direct relationships between brain
ST concentrations and those in different CSF locations, and
unbound plasma concentrations in the rat. We have focused
on P-gp-mediated efflux transport functionality whereas it
has been reported to function as an influx transporter at the
BCSFB [22, 27]. This could have major implications for
Fig. 3 The visual predictive
check of the compartmental
model. The dots represent the
individual data points and the
gray area represents the 95 %
prediction confidence interval.
The different boxes represent
the plasma, brainECF, CSFLV,
CSFCM and braindeep data
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the relationship between CSF concentrations and brain
ECF concentrations for compounds that are substrates for
P-gp-mediated transport. To investigate the specific con-
tribution of P-gp-mediated transport, quinidine was used as
a paradigm P-gp substrate, with inhibition of P-gp by
co-administration of tariquidar. Tariquidar is known to
inhibit P-gp with a half-maximum inhibition constant
(IC50) of approximately 25 ng/ml [59]. Previous work by
Bankstahl et al. [60] and Syva¨nen et al. [61] have indicated
that a 15 mg/kg dose of tariquidar results in plasma and
brain concentrations over 50-fold higher than the IC50
value up to 3 h after administration. Therefore, it is plau-
sible to assume that the dose of tariquidar is sufficient to
fully inhibit P-gp throughout the entire experimental per-
iod. Advanced mathematical modelling was used to finally
determine the interaction between systems physiology and
quinidine. Our key findings indicated that: (1) brainECF-
and CSF-to-unbound plasma AUC0–360 ratios were all over
100 %, indicating influx transport by using unbound con-
centrations; (2) P-gp also restricts brain intracellular
exposure; (3) a direct transport route of quinidine from
plasma to brain cells exists; (4) P-gp-mediated efflux of
quinidine at the BBB seems to result of combined efflux
enhancement and influx hindrance; (5) P-gp at the BCSFB
at the level of the LV functions as an efflux transporter or,
at the CM, is not functioning at all.
In previous studies brainECF concentrations were esti-
mated on the basis of total brain concentrations and the
brain unbound fraction, determined by equilibrium dialysis
of drug-spiked brain homogenates [6–8]. However, brain
tissue homogenization destroys cell structures unmasking
binding sites that are normally not accessible to a drug [9],
potentially leading to underestimation of the in vivo brain
unbound fraction. The use of the brain slice technique is an
improvement [62]. Liu et al. [8], and Fride´n et al. [10],
have applied this technique to calculate the brain unbound
fraction, being further used to estimate brainECF concen-
trations. Comparison of the brain homogenate method with
brain slice technique indicated that the brain unbound
fraction was over 50 % different for 5 out of 7 compounds
[8]. Liu and colleagues [9] have later applied the micro-
dialysis technique for direct measurement of unbound
brainECF concentrations and compared those to CSF con-
centrations sampled at steady-state. They found that the
ratio of CSF over brainECF concentrations was larger for 1
out of the 7 P-gp substrates.
To our surprise, we found that unbound concentrations
in brain were significantly larger than unbound concen-
trations in plasma. This appears to be in contrast to pre-
vious studies by Liu et al. [9] and Kodaira et al. [63] in
which unbound brain-to-unbound plasma (brainu/plasmau)
concentration ratios at assumed steady state were well
below unity. While our results were quite comparable to
the results of Liu et al. [9] and Kodaira et al. [63], a sub-
stantial difference was found for the (calculated) unbound
brain (ECF) concentrations between these studies, and
ours. Liu et al. determined the brain free fraction with the
brain homogenate method and found an unbound brain
fraction comparable to the unbound brain fraction that was
found by Kodaira et al. by the brain slice technique (3.6
and 2.4 %, respectively). In contrast, the unbound brain
fraction in our study was calculated to be 28 % (brainECF
concentration divided by the total brain concentration).
However, Liu et al. reported a 3-fold difference in the
brainu concentrations when calculated on the basis of the
brain homogenate free fraction, compared to using micro-
dialysis data when corrected for in vitro recovery [9]. We
measured both in vitro (33 %) and in vivo recovery (9 %),
and found that the in vivo recovery was 3.5-fold lower. If
we would calculate the brainECF/plasmau concentration
ratio at maximal concentrations, like Liu et al. did, and
Fig. 4 Diagram of the SBPK model that was used to describe the
intra-brain distribution in the rat. CLE is the elimination clearance
from plasma, QPL–PERx is the inter-compartmental clearance between
plasma and the first (x = 1) or second (x = 2) peripheral compart-
ment. Further, for transfer clearances between compartments (CLfrom
comp-to comp), denotations of the compartments are: PL plasma; ECF
brainECF; DBR braindeep; LV lateral ventricle; TFV third and fourth
ventricle; CM cisterna magna and SAS subarachnoid space. QECF is
the flow rate of brain ECF, QCSF is the flow rate of CSF. For
peripheral and plasma compartments, V volume of distribution; for
brain compartments, V volume, not shown in the diagram
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assume that for Liu also a 3.5-fold lower in vivo recovery
would apply, then the brainECF/plasmau concentration ratio
would be comparable to ours.
For the brainECF/plasmau AUC0–360 ratios, we found
values significantly larger than unity as in the elimination
phase the rate of decline in plasma concentrations was
larger than those observed in CSF and brainECF. We cannot
compare these findings with Kodaira and Liu because their
studies did not include an elimination phase.
Therefore, based on our data, it appears that quinidine is
also transported by other transporters at the BBB and
BCSFB, in the direction of the brain. However, there is no
direct information in literature to support this. We could
only find the following potential contributions: Van
Montfoort et al. [64] reported that quinidine is transported
by OCTs. This observation was made in an in vitro study,
and was found to occur for a pH of 6, but not significantly
at pH 7.4. The question remains how this relates to the
Table 4 Final estimation of the rat PK parameters for the different SBPK models (±standard error)
Parameter Efflux enhancement Influx hindrance Efflux enhancement and influx hindrance
Objective function value 18,105 18,030 17,969
CLE 81.6 ± 11.4 ml/min 87.4 ± 10.5 ml/min 95.9 ± 11.0 ml/min
P-gp effect on CLE 1.9 ± 0.2-fold increase 2.1 ± 0.3-fold increase 1.9 ± 0.2-fold increase
QPL–PER1 1,520 ± 177 ml/min 1,150 ± 138 ml/min 1,190 ± 135 ml/min
QPL–PER2 84.2 ± 57.6 ml/min 360 ± 105 ml/min 333 ± 94 ml/min
CLPL–DBR,p 1,540 ± 182 ll/min 2,670 ± 501 ll/min 2,180 ± 384 ll/min
CLPL–DBR,P-gp NA 2,430 ± 466 ll/min 1,900 ± 373 ll/min
CLDBR–PL,p 17.8 ± 1.5 ll/min 48.5 ± 9.6 ll/min 37.2 ± 7.2 ll/min
CLDBR–PL,P-gp 253 ± 40.4 ll/min NA 19.6 ± 10.9 ll/min
CLPL–ECF,p 48.6 ± 6.3 ll/min 68.4 ± 9.1 ll/min 50.2 ± 5.0 ll/min
CLPL–ECF,P-gp NA 54.8 ± 8.1 ll/min 33.8 ± 5.1 ll/min
CLECF–PL,p 7.1 ± 1.2 ll/min 9.3 ± 1.4 ll/min 6.3 ± 0.8 ll/min
CLECF–PL,P-gp 33.1 ± 8.1 ll/min NA 5.3 ± 1.7 ll/min
CLPL–LV,p 7.2 ± 0.8 ll/min 8.4 ± 0.8 ll/min 9.0 ± 0.9 ll/min
CLPL–LV,P-gp NA 3.0 ± 0.7 ll/min 3.8 ± 0.8 ll/min
CLLV–PL,p 0.03 ± 0.01 ll/min 0.04 ± 0.01 ll/min 0.04 ± 0.01 ll/min
CLLV–PL,P-gp 1.2 ± 0.4 ll/min NA 0 ll/min
CLPL–CM,p 1.3 ± 0.3 ll/min 1.1 ± 0.3 ll/min 1.1 ± 0.3 ll/min
CLPL–CM,P-gp NA 0 ll/min 0 ll/min
CLCM–PL,p 3.7 ± 0.5 ll/min 4.0 ± 0.5 ll/min 4.1 ± 0.5 ll/min
CLCM–PL,P-gp 0 ll/min NA 0 ll/min
QECF 0.2 ll/min [39, 46] 0.2 ll/min [39, 46] 0.2 ll/min [39, 46]
QCSF 2.2 ll/min [47] 2.2 ll/min [47] 2.2 ll/min [47]
VPL 10.6 ml [52] 10.6 ml [52] 10.6 ml [52]
VPER1 13.2 ± 1.8 l 6.4 ± 1.6 l 6.8 ± 1.7 l
VPER2 5.8 ± 2.6 l 13.9 ± 2.0 l 13.3 ± 2.2 l
VDBR 1.44 ml [38] 1.44 ml [38] 1.44 ml [38]
VECF 290 ll [39] 290 ll [39] 290 ll [39]
VLV 50 ll [41, 42] 50 ll [41, 42] 50 ll [41, 42]
VTFV 50 ll [43] 50 ll [43] 50 ll [43]
VCM 17 ll [44, 45] 17 ll [44, 45] 17 ll [44, 45]
VSAS 180 ll [40, 43] 180 ll [40, 43] 180 ll [40, 43]
gCL10 0.20 ± 0.09 0.16 ± 0.08 0.14 ± 0.06
ePL 0.29 ± 0.04 0.22 ± 0.02 0.22 ± 0.03
eDBR 0.06 ± 0.01 0.07 ± 0.02 0.07 ± 0.02
eECF 0.07 ± 0.01 0.07 ± 0.01 0.06 ± 0.01
eLV 0.10 ± 0.01 0.10 ± 0.01 0.11 ± 0.02
eCM 0.06 ± 0.01 0.07 ± 0.01 0.08 ± 0.02
Parameter values in italic are derived from literature; NA implicates that the parameter is not available in the specific model
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in vivo situation, like ours. Giacomini et al. [65] stated that
quinidine is a potential inhibitor of OCTs. OCTs have been
localized both at the BBB [66], as well as at the BCSFB
[67]. Thus, the possibility of active influx transport for
quinidine at the BBB and BCSFB remains to be further
investigated. Alternatively, it could reflect a passive ‘‘ion-
trapping’’ process, governed by lower pH values in brain
ECF (pH *7.3) than in plasma (pH *7.4). However, as
quinidine is a diprotic base with pKas 4.2 and 7.9 [30], the
low difference between the % ionized at pH 7.3 (80 %) and
pH 7.4 (76 %) does not seem to explain our findings.
According to the ‘‘smaller than threefold concentration
ratio paradigm’’ [7], differences between brainECF and CSF
concentrations of quinidine as found in this study (on
average 0.72 ± 0.20) would be considered pharmacoki-
netically irrelevant. However, upon co-administration of
tariquidar this ratio increased 3.1-fold (to the value of
2.22 ± 0.57). This means that P-gp functionality and vari-
ations thereof may have an important effect on the brai-
nECF–CSF ratio and the extrapolation from rats to humans,
as is discussed by de Lange [68, 69]. However, quinidine is
a strong P-gp substrate and it remains to be investigated
what the impact of P-gp functionality on the brainECF–CSF
concentration relationships would be for weaker substrates.
Several different models for P-gp-mediated transport
have been suggested. [28, 51, 56, 57, 70–72]. The first model
is described as the ‘‘classical pump model’’ in which a P-gp
substrate is transported from the cytosol to the extracellular
space against a concentration gradient (so-called ‘‘efflux
enhancement’’). [51, 56, 70–72] The second model can be
described as a ‘‘vacuum cleaner model’’ in which a lipophilic
compound that is diffusing across the cellular membrane, is
interacting with P-gp within the lipid bilayer of the cellular
membrane and is then transported back into the extracellular
space. [28, 70–72] The third model is described as the
‘‘flippase model’’ in which a lipophilic compound within the
lipid bilayer at the cytosolic side is flipped to the extracellular
side where it diffuses back into the extracellular space.
[51, 56, 57, 70–72] In the second and third model P-gp
prevents the entry of compounds to the brain by a process
which is called ‘‘influx hindrance’’. Based on the SBPK
modeling results, it appears that for quinidine P-gp acts via
combined influx hindrance and efflux enhancement. This is
in line with the localization of P-gp at both the luminal and
abluminal membrane of the BBB [21].
For the potential role of P-gp at the BCSFB, there have
been some indications that P-gp could function as an influx
transporter at the BCSFB [22, 27]. We anticipated this to
be among our findings, however, with our data we could
not identify P-gp influx at the level of the BCSFB. Instead,
the results of the SBPK modelling suggest that P-gp at the
BCSFB functions as an efflux transporter (LV) or is not
functioning at all (CM).
Then, interestingly, the co-administration of tariquidar
results in an increase of the total brain-to-brainECF con-
centration ratio, which has also been observed in an earlier
study on quinidine at our lab by Syva¨nen et al. [32]. This
indicates that P-gp is also located beyond the BBB at the
parenchymal and perivascular astrocytes, which is in line
with several reports [73–78].
In our current study we obtained in parallel brain ST, CSF
and plasma concentration–time profiles, under dynamic con-
ditions, included corrections for in vivo probe recoveries, and
plasma protein binding to finally obtain unbound concentra-
tions in these body compartments. It is anticipated that this
approach, combined with advanced mathematical modelling,
Fig. 5 The visual predictive
check of the final SBPK model.
The dots represent the
individual data points and the
gray area represents the 95 %
prediction confidence interval.
The x axis represents the time
(min) and the y axis represents
the quinidine concentrations
(ng/ml). The different boxes
represent the plasma, brain
ECF, CSFLV, CSFCM and
braindeep data, respectively
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will further improve revealing the mechanisms underlying the
relationship between brainECF and CSF concentrations than
will steady-state and/or single end-of-experiment CSF con-
centrations [79]. Having information on concentration–time
profiles following a single administration is relevant as we
need time-dependent data to decipher the rate and extent of
processes of drug transport into, within, and out of the brain
[80]. It provides the best basis to further explore the multiple
dose regimens as used in the clinic, for which it is know that a
true steady state condition is actually not reached.
Finally, in striving towards reduction on the use of
animals on one hand, and the fact that systematic studies on
the inter-relationship of plasma PK, BBB transport and
intra-brain distribution, cannot be performed in human, the
use of the multiple microdialysis probe approach [20],
obtaining a total of 84 samples per animal, results in a great
reduction in the number of animals required for these type
of studies compared to the single time point measurements.
Conclusion
It is concluded that in parallel obtained data on unbound
brainECF, CSF and plasma concentrations, under dynamic
conditions, combined with advanced mathematical model-
ling is a most valid approach to reveal the mechanisms
underlying the relationship between brainECF and CSF con-
centrations, which is significantly influenced by activity of
P-gp. This indicates that information on functionality of P-gp
is important for the prediction of human brain target site
concentrations of P-gp substrates on the basis of human CSF
concentrations, and provides further guide to unravelling
mechanisms and drug properties that govern the transport
into, within, and out of the brain, for translational purposes.
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Appendix
Differential equations
The mass balance equations describing the final SBPK
model were expressed as follows.
Plasma:
dApl;u=dt ¼ dose  kPLPER1Apl;u þ kPER1PLAPER1
 kPLPER2Apl;u þ kPER2PLAPER2
 kPLDBRApl;u þ kDBRPLADBR  kPLECFApl;u
þ kECFPLAECF  kPLLVApl;u þ kLVPLALV
 kPLTFV Apl;u þ kTFVPLATFV  kPLCMApl;u
þ kCMPLACM þ ðQCSF=VSASÞASAS  kEAPL;u
CPL;u ¼ APL;u=VPL
Periphery:
dAPER1=dt ¼ kPLPER1APL;u  kPER1PLAPER1
CPER1 ¼ APER1=VPER1
dAPER2=dt ¼ kPLPER2APL;u  kPER2PLAPER2
CPER2 ¼ APER2=VPER2
Braindeep:
dADBR=dt ¼ kPLDBRAPL;u  kDBRPLADBR
CDBR ¼ ADBR=VDBR
BrainECF:








dATFV=dt ¼ kPLTFV APL;u  kTFVPLATFV
þ ðQCSF=VLVÞALV  ðQCSF=VTFVÞATFV
CTFV ¼ ATFV=VTFV
CSFCM:
dACM=dt ¼ kPLCMAPL;u  kCMPLACM
þ ðQCSF=VTFVÞATFV  ðQCSF=VCMÞACM
CCM ¼ ACM=VCM
CSFSAS:
dASAS=dt ¼ ðQCSF=VCMÞACM  ðQCSF=VSASÞASAS
CSAS ¼ ASAS=VSAS
where kE ¼ ðCLE;p þ CLE;PgpÞ=VPL;
kPLPER1 ¼ QPLPER1=VPL; kPER1PL ¼ QPLPER1=VPER1;
kPLPER2 ¼ QPLPER2=VPL; kPER2PL ¼ QPLPER2=VPER2;
kPLDBR ¼ ðCLPLDBR;p  CLPLDBR;PgpÞ=VPL;
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kDBRPL ¼ ðCLDBRPL;p þ CLDBRPL;PgpÞ=VDBR;
kPLECF ¼ ðCLPLECF;p  CLPLECF;PgpÞ=VPL;
kECFPL ¼ ðCLECFPL;p þ CLECFPL;PgpÞ=VECF;
kPLLV ¼ ðCLPLLV ;p  CLPLLV ;PgpÞ=VPL;
kLVPL ¼ ðCLLVPL;p þ CLLVPL;PgpÞ=VLV ;
kPLTFV ¼ ðCLPLTFV ;p  CLPLTFV ;PgpÞ=VPL;
kTFVPL ¼ ðCLTFVPL;p þ CLTFVPL;PgpÞ=VTFV ;
kPLCM ¼ ðCLPLCM;p  CLPLCM;PgpÞ=VPL; and
kCMPL ¼ ðCLCMPL;p þ CLCMPL;PgpÞ=VCM:
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